Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 16, 2026, 6:21 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 5,568 matching trials from the live ClinicalTrials.gov search.
Conditions
Sporadic Inclusion Body Myositis (sIBM), Idiopathic Inflammatory Myopathies
Interventions
Pozelimab/Cemdisiran
Combination Product
Lead sponsor
Austin Neuromuscular Center
Other
Eligibility
45 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Austin, Texas
Conditions
Solid Tumor, Non Small Cell Lung Cancer, Neuroendocrine Carcinoma, Renal Cell Carcinoma (RCC)
Interventions
VSV-IFNβ-NIS, Pembrolizumab, ipilimumab + nivolumab
Biological
Lead sponsor
Vyriad, Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Rochester, Minnesota • Cleveland, Ohio
Conditions
Advanced Cancer, Refractory Cancer, Tumor Gastric
Interventions
PCS6422 and capecitabine
Drug
Lead sponsor
Processa Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
6
States / cities
Omaha, Nebraska • New Brunswick, New Jersey • Santa Fe, New Mexico + 3 more
Conditions
Hepatitis C
Interventions
SOF/VEL/VOX, SOF/VEL
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
943 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
47
States / cities
Long Beach, California • Los Angeles, California • Palo Alto, California + 44 more
Conditions
Hidradenitis Suppurativa
Interventions
Photodynamic Therapy
Procedure
Lead sponsor
University of Kansas
Other
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Kansas City, Kansas
Conditions
Pneumonia, Bacterial, Community-Acquired Infections, Nosocomial Infection, Pneumonia, Ventilator-Associated
Interventions
Cefepime placebo, Cefepime, Doripenem, Doripenem placebo, Amoxicillin/clavulanate potassium
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
3 Months to 18 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Little Rock, Arkansas • Cleveland, Ohio • Toledo, Ohio + 1 more
Conditions
Systemic Sclerosis
Interventions
Belimumab, Mycophenolate Mofetil, Placebo Infusion
Drug · Other
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New York, New York
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
AGS-003-LNG, Carboplatin, Abraxane, Alimta, Cisplatin, Taxol, Radiation Therapy
Biological · Drug · Radiation
Lead sponsor
GU Research Network, LLC
Other
Eligibility
19 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Omaha, Nebraska
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
salmonella VNP20009, cefixime, ceftriaxone sodium, ciprofloxacin, trimethoprim-sulfamethoxazole
Biological · Drug
Lead sponsor
Vion Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
3
States / cities
Boston, Massachusetts • Cleveland, Ohio • Dallas, Texas
Conditions
HIV Infections
Interventions
Indinavir sulfate
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
16 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
29
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 20 more
Conditions
HIV
Interventions
Emtricitabine and tenofovir disoproxil fumarate
Drug
Lead sponsor
Philadelphia Fight
Other
Eligibility
18 Years to 30 Years · Male only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Asthma
Interventions
Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID, Fluticasone propionate 250 mcg BID
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
621 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
58
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Fountain Valley, California + 48 more
Conditions
Non-Small Cell Lung Cancer
Interventions
Adjuvant Chemotherapy, Radiographic surveillance, 14-Gene Prognostic Assay
Drug · Other
Lead sponsor
Razor Genomics
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
18
States / cities
Mission Viejo, California • Sacramento, California • Santa Rosa, California + 15 more
Conditions
Transplant Failure or Rejection of Bone Marrow (Graft vs Host Disease, GVHD)
Interventions
Ruxolitinib, LBP- MARCO
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Conditions
Cystic Fibrosis
Interventions
LUM/IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
2 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
17
States / cities
Palo Alto, California • Aurora, Colorado • Chicago, Illinois + 14 more
Completed Phase 2 Interventional Results available

AFQ056 for Language Learning in Children With FXS

NCT02920892
Conditions
Fragile X Syndrome
Interventions
AFQ056, Placebo, Language Intervention
Drug · Other
Lead sponsor
Elizabeth Berry-Kravis
Other
Eligibility
32 Months to 6 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
14
States / cities
Davis, California • Denver, Colorado • New Haven, Connecticut + 11 more
Conditions
Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Hodgkin Disease, Lymphoma, Lymphoma, B-Cell, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Melanoma, Neoplasm Metastasis, Neoplasms, Head and Neck, Neoplasms, Squamous Cell, Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer Metastatic, Non-small Cell Carcinoma, Squamous Cell Cancer, Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Neoplasm, Lymphoma, Non-Hodgkin, Pancreatic Adenocarcinoma
Interventions
Intravenous (IV) SEA-CD40, Pembrolizumab, Subcutaneous (SC) SEA-CD40, Gemcitabine, Nab-paclitaxel
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
19
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 15 more
Completed Phase 2 Interventional Results available

Dose Ranging Study of Carbidopa-levodopa

NCT03023059
Conditions
Age-related Macular Degeneration
Interventions
Carbidopa-Levodopa, 25 Mg-100 Mg Oral Tablet
Drug
Lead sponsor
Snyder, Robert W., M.D., Ph.D., P.C.
Individual
Eligibility
50 Years to 85 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Tucson, Arizona
Conditions
Advanced Solid Tumor
Interventions
BGB-58067, BG-89894, Standard of Care Therapy, RAS(ON) Inhibitors
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
695 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
12
States / cities
Los Alamitos, California • Los Angeles, California • Celebration, Florida + 8 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Intra-Individual Reproducibility of the Non-Invasive Assessment of the Portal Circulation

NCT01579162
Conditions
Hepatitis C, Chronic, Non-Alcoholic Fatty Liver Disease
Interventions
Cholate-24-13C (IND 65121) & Cholate-2,2,4,4-d4 (IND 65123)
Device
Lead sponsor
HepQuant, LLC
Industry
Eligibility
22 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Breast Cancer, Metastatic Breast Cancer, Stage IV Breast Cancer
Interventions
Ixabepilone, Capecitabine, Motesanib
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Liver Cancer
Interventions
bevacizumab, chemotherapy, embolization therapy, hepatic artery infusion
Biological · Drug · Procedure
Lead sponsor
Yale University
Other
Eligibility
18 Years to 120 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Gastric Cancer, Stomach Cancer
Interventions
Paclitaxel, Carboplatin, Dexamethasone, Diphenhydramine, Famotidine, Palonosetron, 3D conformal or intensity modulated radiotherapy, Surgical resection, Adjuvant Chemotherapy
Drug · Radiation · Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
3
States / cities
New York, New York
Completed No phase listed Observational Accepts healthy volunteers

Study to Assess the PK Profile of NanoBUP Capsules Relative to Suboxone

NCT01260675
Conditions
Healthy
Interventions
Buprenorphine HCl/Naloxone HCl
Drug
Lead sponsor
NanoSHIFT LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
San Antonio, Texas